Get Support – Call 1-888-MITO-411

The Mito Disease Drug Development Journey

Print Friendly, PDF & Email

Join Dr. Matt Klein from PTC Therapeutics , MitoAction and Cure Mito for an exclusive webinar discussing the history of clinical research in Leigh Syndrome, the evolution of PTC-743 and the MIT-E Study!

About the Speaker

Matthew Klein, MD, MS, FACS

Matthew Klein, MD, MS, FACS

Dr. Matthew B. Klein, MD, MS, FACS is Chief Development Officer at PTC Therapeutics, Inc. Prior to joining PTC, Dr. Klein was CEO and Chief Medical Officer of BioElectron Technology Corporation, a biotechnology company focused on development of redox active small molecules for mitochondrial disease and related disorders of oxidative stress. Prior to joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. Dr. Klein completed his undergraduate degree at the University of Pennsylvania where he graduated summa cum laude and Phi Beta Kappa, and received his MD degree with honors from Yale University.

Upcoming Events

View All
View Calendar

Expert Series

View All

Last Presentation

Expert Series: Mitochondrial Disease and PMM
Presented September 11, 2024

P.O. Box 310
Novi, MI 48376
(888) 648-6228
info@mitoaction.org